After scrapping its obesity pill program over safety issues, Pfizer is looking at acquisitions to revive its cardiometabolic pipeline. The company faces long-term challenges including patent cliffs, regulatory threats from possible drug pricing changes, and waning investor confidence. Although it's cutting costs and investing in its R&D pipeline to steady the ship, Wall Street doubts Pfizer can replace the massive earnings it made during the COVID boom with new blockbuster drugs.
